Evidence map›Paper›PMID 38904792›Full record

ReviewJournal of neural transmission (Vienna, Austria : 1996)2024

Anticholinergic drugs for parkinsonism and other movement disorders.

Peter A LeWitt, Luke Hong, Mark S Moehle

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neural transmission (Vienna, Austria : 1996), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Peter A LeWittDepartments of Neurology, Wayne State University School of Medicine and Henry Ford Hospital, 8-D 4201 St. Antoine Street, Detroit, MI, 48201, USA. aa1142@wayne.edu.ORCID 0000-0002-4976-4445
Luke HongThe Department of Neurology, University of South Florida, Tampa, FL, USA.
Mark S MoehleDepartment of Pharmacology and Therapeutics, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA.

Funding

M4 muscarinic acetylcholine receptor signaling as a potent regulator of motor deficitsR00NS110878 · NINDS · UNIVERSITY OF FLORIDA · PI MOEHLE, MARK S · 2021 to 2023
$742k
NINDS NIH HHS R00 NS110878
6 · The paper itself

Abstract

Anticholinergic (AC) drugs, a medication class that acts by blocking nicotinic and muscarinic acetylcholine receptors, were first utilized for therapeutic purposes in the mid-19th century. Initial applications were as symptomatic therapy for Parkinson disease (PD), a practice continuing to the present. Initially, the AC drugs used were naturally-occurring plant compounds. Synthetic AC drugs were developed in the late 1940s and predominated in neurological therapeutics. Until the advent of pharmaceuticals acting upon striatal dopaminergic motor pathways, AC drugs provided the only effective means for lessening tremors and other clinical problems of the PD patient. However, because dopaminergic compounds are so effective at meeting the needs of the typical PD patient, AC medications are far less utilized by clinicians today. In recent years, there has been only a few investigations of AC drugs as neurological treatments. This review will revisit the clinical landscape of AC pharmacology and application for movement disorders along with recent research in search of improving therapeutics with AC drugs.

Indexed as

Cholinergic AntagonistsMovement DisordersAnimalsHumansParkinson DiseaseParkinsonian DisordersCholinergic AntagonistsAcetylcholineAnticholinergicDystoniaMovement disordersParkinson disease

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.